Clinical Trial Detail

NCT ID NCT02708680
Title Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Recruitment Active, not recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Syndax Pharmaceuticals
Indications

triple-receptor negative breast cancer

Therapies

Atezolizumab

Atezolizumab + Entinostat

Age Groups: adult senior

No variant requirements are available.